Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies
Solange Milolo, Paulina Morales-Ruíz, Trésor Zola Matuvanga, Gwen Lemey et autres